Borghaei H, Gettinger S, Vokes EE, Chow LQM, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol 2021 Jan 15:JCO2001605. doi: 10.1200/JCO.20.01605.
PMID: 33449799